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We have previously shown that patients with Parkinson’s disease
(PD) perseverate in their choice of action relative to healthy con-
trols, and that this is affected by dopaminergic medication (Hughes
LE, Barker RA, Owen AM, Rowe JB. 2010. Parkinson’s disease and
healthy aging: Independent and interacting effects on action selec-
tion. Hum Brain Mapp. 31:1886–1899). To understand further the
neural basis of these phenomena, we used a new task that manipu-
lated the options to repeat responses. Seventeen patients with
idiopathic PD were studied both “on” and “off” dopaminergic medi-
cation and 18 healthy adults were scanned twice as controls. All
subjects performed a right-handed 3-choice button press task,
which controlled the availability of repeatable responses. The fre-
quency of choosing to repeat a response (a form of perseveration)
in patients was related to dopamine therapy and disease severity
as a “U-shaped” function. For repetitive trials, this “U-shaped”
relationship was also reflected in the BOLD response in the caudate
nuclei and ventrolateral prefrontal cortex. Our results support a
U-shaped model of optimized cortico-striatal circuit function and
clearly demonstrate that flexibility in response choice is modulated
by an interaction of dopamine and disease severity.
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Volitional control of action-selection is supported by a broad
frontoparietal network (Deiber et al. 1991; Jenkins et al. 2000;
Rowe et al. 2005; Forstmann et al. 2008; Rowe, Hughes, Eck-
stein et al. 2008), which is altered in Parkinson’s disease
(PD). For example, patients show abnormal medial frontal
activity (Jenkins et al. 1992; Playford et al. 1992; Jahanshahi
et al. 1995; Rowe et al. 2002), increased motor and lateral pre-
motor activity (Haslinger et al., 2001), reduced cortico-striatal
connectivity (Grafton et al. 1994; Wu, Chan, Hallett et al.
2011; Wu, Wang, Hallett et al. 2011) and a dopamine-sensitive
switch in effective connectivity of the prefrontal cortex, from
the pre-supplementary motor area to the lateral premotor
cortex (Rowe, Hughes, Barker et al. 2010). Dopaminergic
therapies can partially restore normal activity and connectivity
(Jenkins et al. 1992; Rascol et al. 1994; Rowe, Hughes, Barker
et al. 2010; Haslinger et al. 2001; Buhmann et al. 2003), de-
pending on factors such as age and disease severity (Hughes
et al. 2010).
However, dopamine therapy can have differential effects
on the motor and cognitive systems (Cools 2006; MacDonald
et al. 2011), with some functions enhanced and others im-
paired by medication. The contrasting effects of disease and
dopaminergic therapy on different neurocognitive systems
has been explained in terms of differential dopaminergic
depletion/augmentation in distinct nigrostriatal and
cortico-striatal circuits (Alexander et al. 1986). For each
circuit, there is proposed to be an optimal dopaminergic state
that can be described in terms of an inverted U-shaped func-
tion. This function describes improvement in performance
with increasing levels of dopamine up to an optimal point,
the apex of the curve, after which performance decreases
(Williams and Castner 2006; Rowe, Hughes, Ghosh et al.
2008; Cools and D’Esposito 2011). Such a non-linear relation-
ship between dopamine and behavioural performance in PD
may arise, because, clinically, dopaminergic therapy is typi-
cally titrated to optimise motor function. Therefore, non-
motor dopaminergic systems that are dependent on frontal
and striatal networks may be relatively “over-dosed” and
moved further away from their optimum dopaminergic state,
consequently adversely affecting behaviour (Cools et al.
2001a; Cools 2006).
Dopaminergic dysregulation of voluntary and goal-
directed behaviours manifests in extreme cases as impulse
control disorders, such as problem gambling or compulsive
shopping (Voon, Gao, Brezing et al. 2011; Voon, Mehta,
Hallett et al. 2011). One mechanism for these disorders is
modulation of estimated action outcomes in the striatum via
dopaminergic medication, which leads to biased behavioural
choices (Voon et al. 2010). Another form of bias in self-
selected choices has been reported in patients taking dopa-
minergic medication, who have difficulty in suppressing
habitual responses, such as repetition or counting (Robert-
son et al. 1996; Brown et al. 1998; Dirnberger et al. 2005),
and this bias is thought to be modulated by fronto-striatal
circuits (Jahanshahi et al. 2000; Dirnberger et al. 2005). Per-
severation of responses in the face of corrective feedback
has also been observed in PD. For example, reversal and
non-reversal shifts in rule-learning or task-set are impaired
in patients “on” medication (Owen et al. 1993; Lewis et al.
2005; Slabosz et al. 2006; Rutledge et al. 2009). However,
the perseveration of responses in these studies may arise for
several reasons, including differential sensitivity to reward or
punishment, learned irrelevance or deficits in attentional
shifting. These reasons of perseveration are distinct from the
potential to repeat or explore new actions in the absence of
explicit reward or learned rules.
In a previous action-selection task, we observed that
patients with PD “on” medication repeatedly selected the
same response in their action-selection decisions, and
response repetition in these patients was linearly related to
disease severity. However, this repetitive behaviour was not
observed when patients were acutely withdrawn from their
dopamine medication (Hughes et al. 2010). This is in contrast
to healthy adults who, whilst not behaving randomly, are
© The Authors 2012. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cerebral Cortex July 2013;23:1572–1581
doi:10.1093/cercor/bhs144
Advance Access publication June 1, 2012
typically biased away from repetitions of responses (Baddeley
et al. 1998; Brown et al. 1998).
Perseveration might result from dysregulation of inhibition,
associated with impairment of prefrontal cortex (cf. Aron et al.
2004; Aron 2007) or the caudate nucleus (Aron et al. 2003). For
example, severe caudate nuclei loss in Huntington’s disease is
associated with perseverative responding in a variety of motor
and cognitive tasks (Lawrence et al. 1999; Aron et al. 2003). A
role for the caudate nucleus in perseverative responses is also
shown in adults with a regular use of dopaminergic stimulant
drugs (e.g. cocaine and amphetamine) (Ersche et al. 2011). In
stimulant users, the normal relationship between caudate
nucleus activation and response perseveration was reversed by
dopamine agonists, suggesting an interaction between acute
and chronic dopamine dysregulation in the caudate nucleus,
leading to abnormal behavioural decisions.
Action-selection paradigms which reveal fronto-striatal
activity could be utilized to examine perseverative respond-
ing; however, there is a potential problem in earlier studies of
response selection. When making a selection on a current
trial, the available response options (typically buttons or
numbers) tend to include the option to repeat a previous
response, whilst sometimes also explicitly instructing subjects
not to use repetitive sequences (Jenkins et al. 1992; Playford
et al. 1992; Haslinger et al. 2001), which confounds the selec-
tion of a new action with the memory of prior moves. The
selection of unique responses, using trial specific stimuli (Lau
et al. 2004), single words (Desmond et al. 1998) or first-only
responses in healthy controls (Rowe, Hughes, Nimmo-Smith
et al. 2010), partly overcomes this confound but is inconsist-
ent in the distinction between the roles for the prefrontal
cortex and striatum.
In the current study, we further examined action-selection
in PD, and the role of dopaminergic therapy and disease se-
verity in behaviour. In particular, we sought to examine rep-
etitions or inhibitions of previous actions and to identify the
role of prefrontal cortex and caudate nucleus in these
decisions. By manipulating response options in an action-
selection task we were able to examine response selection
both with and without the option to repeat. We predicted that
when repetition was available, patients with PD would be
more likely to perseverate. We further predicted that dopa-
minergic therapy and disease severity would interact, as we
have previously observed, to influence both the repetitive be-




Twenty patients (aged 51–78) with idiopathic PD were recruited from
the Cambridge Centre for Brain Repair’s PD research clinic, using the
United Kingdom PD Brain Bank clinical diagnostic criteria. Patients
were tested once on their usual dopaminergic medication (“on”) and
once after dopaminergic mediation had been withdrawn (“off”:
minimum 12 h withdrawal for short-acting preparations, 24 h for
long-acting preparations). They were examined on both occasions
immediately before the scanning session using the UPDRS (Unified
PD Rating Scale—III) motor rating scale (Fahn and Elton 1987) and
classified according to the Hoehn and Yahr (Hoehn and Yahr 1967)
and Schwab and England (Schwab and England 1969) rating scales.
All but 1 subject reduced the UPDRS motor subscale III score when
“off medication” (see Table 1).
The val158met COMT genotype was determined for the patients
and covered all 3 polymorphisms, but the numbers were not sufficient
Table 1
Demographic details of patients
No. Age UPDRS Hoehn
and Yahr
Schwab and England MMSE COMT genotype LEDD PD medications (mg/day) Other medications
On Off On Off
1 60 9 22 2.0 2.5 90 29 Val/Met 1170 A 200, M 150, P2.55 n/a
2 57 6 18 1.0 2.0 100 29 Val/Val 1340 P 2.1, S+ 500 Flu
3* 71 10 × 1.0 × 80 29 Val/Met 900 Ro 15, S 300 Sim
4 72 16 36 2.0 3.0 90 28 Val/Val 1440 A 100, P 2.1, S 600 Clo, Fur, Lis, Lan, Mod, Sim
5 51 7 23 2.0 2.0 90 28 Met/Met 1080 M 200, P2.1, Se 10 n/a
6 64 7 18 1.5 1.5 70 29 Met/Met 2056 P 2.64, S 400, S+ 600 Ami, CC, CA
7 69 18 19 2.0 2.0 80 28 Val/Met 1780 A 100, M 450, Ro 16, St 500 Clo, Flu, Ind, Lev, Ome
8 73 3 24 1.5 1.5 80 29 Val/Met 1380 R 21, St 450 Ami, Aml, Per, Sim
9 78 17 16 3.0 3.0 80 26 Val/Met 1720 Ra 1, Ro 16, St 450 Aml, TH
10 59 9 28 2.0 2.0 80 30 Val/Val 1360 Ro 24, S 400 Asp, BF, Sim
11 68 14 18 2.0 2.5 60 27 – 1920 A 400, E 1000, M 1000, Ro 18 Clo, Flu, Mac
12 74 10 31 2.5 3.0 90 29 Met/Met 1660 M 700, Ro 24 Asp, Irb, LH
13 53 19 32 2.0 2.5 70 27 Val/Met 1740 A 200, P 3.15, St 400 n/a
14* 64 8 × 2.0 × 90 29 Val/Met 1680 A 200, E 1200, Ro 24, S 600 Ami, Mac, Qui
15 63 15 18 2.0 2.0 70 28 Val/Met 840 E 600, Ro 12, S+ 300 n/a
16 59 8 28 2.0 2.5 80 30 Val/Met 1188 S 600, St 300, Se 5 CH, PE, ST
17 73 11 16 2.0 2 80 29 Val/Met 1160 Ro 24, S 200 Cit, Mod
18* 63 12 × 2.0 × 80 29 Val/Val 2160 A 400, M 900, P 3.15 Pro, SC
19 74 6 18 2.0 2.0 100 27 Val/Val 1560 Ra 1, Ro 24, S+ 500 Ami, BF, Lev Ram
20 64 4 20 2 2.0 80 30 Val/Met 510 M 125, St 300 Liv, Mac, Ven
Patient Average 10 m, 10f 65.5 10.5 22.2 1.9 2.2 82.0 28.5 1388
Control Average 13 m, 7 f 65.2 29.0
UPDRS, Unified Parkinson’s Disease Rating Scale motor subscale III; MMSE, Folstein Mini-Mental State Examination. LEDD = L-DOPA equivalent dose: [levodopa (×1.2 if COMT inhibitor)(×1.2 if 10 mg
of S or ×1.1 if 5 mg of S)] + [P × 400] + [R × 40] + [C × 160] + [pergolide × 200] + [bromocriptine × 10] + [lisuride × 160]; all doses are in milligrams (Williams-Gray 2007). *3 patients did not
complete both sessions; “–“ unknown COMT Genotype.
Parkinson’s Medications: A, Amantadine, E, Entacapone; M, Madopar; P, Pramipexole; Ra, Rasagiline; R0, Ropinirole; Se, Selegiline; S, Sinemet; S+, Sinemet plus; St, Stalevo. Other medications: Ami,
Amitriptyline; Aml, Amlodipine; Asp, Aspirin; BF, Bisoprolol fumarate; CC, Candesartan cilexetil; CH, Cetirizine hydrochloride; Cit, Citalopram; Clo, Clonazepam; CA, Co-amilozide; Flu, Fluoxetine; Fur,
Furosemide; Ind, Indepamide; Irb, Irbesartan; Lan, Lansoprazole; LH, Lercanidipine hydrochloride; Lev, Levothyroxine; Lis, Lisinopril; Liv, Liviol; Mac, Macrogol; Mod, Modafinil; Ome, Omeprazole; PE,
Perindopril,erbumine; Pro, Propanolol; Qui, Quinine; Ram, Ramipril; ST, Senna Tablets; SC, Sildanefil citrate; Sim, Simvastatin; TH, Tamsulosin hydrochloride; Ven, Venlafaxine.
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for further analysis. The “on” and “off” sessions were randomized and
counterbalanced across patients. Three patients were excluded prior
to imaging analysis due to incomplete data from their “off” session,
and 1 patient who chose to not repeat any previous response. Eigh-
teen healthy older adults (age 50–75) were recruited from the volun-
teer panel of the MRC Cognition and Brain Sciences Unit and also
completed 2 sessions. They were randomly assigned to a nominal
“on” or “off” status to permit a pseudofactorial design. Within both
patient and control groups, the “on” and “off” sessions were counter-
balanced to minimise practice effects and to introduce sessional var-
iance. Subject details are summarized in Table 1.
All subjects were right handed, not depressed, nor demented (re-
confirmed within the study by the MMSE). No subjects in the healthy
control group had a history of significant neurological or psychiatric
illness, nor cognitive complaints. The study was approved by the local
Research Ethics Committee and participants gave written informed
consent according to the 1991 Declaration of Helsinki.
Task
The “three-choice action-selection” task used is a visually cued right-
hand button press task adapted from previous “4-choice” tasks
(Hughes et al. 2010; Rowe, Hughes, Nimmo-Smith et al. 2010; Rowe,
Hughes, Barker et al. 2010). Subjects were presented with a picture of
a right hand and in response to a cue, pressed a single button with 1
of their 4 right-hand fingers. The cue was either a “specified” cue in
which a single opaque circle indicated which finger to press, or an
“action-selection” cue in which 3 opaque circles indicated the 3
options subjects could choose between (see Fig. 1). In the action-
selection condition, subjects were asked to choose between any of
the 3 response options, making a fresh choice on each action-
selection trial disregarding previous responses. They were not asked
to make “random” responses, nor to avoid sequences.
The task comprised 80 specified trials (20 for each finger) and 80
action-selection trials, interspersed with 80 null events in which no
cue was presented, to enhance model efficiency. Fifty percent of the
specified trials were a repeat response of the previous trials, 50% of
the action-selection trials had an option to repeat the response and
50% of all trials enforced a switch to an alternate response. Thus,
based on the behaviour, there were 3 different types of action-
selection trials: repeat trials, where subjects repeated the same
response as the previous trial, and 2 types of trials in which an alter-
nate action was switched to: repeat-reject trials, where a repeat option
was available but not selected, and non-repeat trials in which a repeat
was not available. There were 2 types of specified trials: repeat and
non-repeat.
Cues were presented for 1 s with a stimulus onset asynchrony of
2.2 s and were randomly intermixed excluding 4 or more sequential
trials of the same type (action-selection, specified or null). The pres-
entation of data was controlled using Cogent 2000 software (www.
vislab.ucl.ac.uk/Cogent2000) using Matlab 7.1 (www.mathworks.
com) in Windows XP (www.microsoft.com). Reaction times and
response accuracy were analysed in SPSS 11.0 (SPSS Inc., Chicago)
using repeated measures analysis of variance and using Greenhouse–
Geisser correction for non-sphericity where appropriate. The fre-
quency of repeating the previous button press in action-selection
trials was calculated as a proportion of the number of trials in which
a repeat option was available (i.e. number of repeats/number of trials
with a repeat option available).
MRI Data Acquisition and Analysis
A Siemens Tim Trio 3 Tesla scanner was used to acquire BOLD-
sensitive T2*-weighted echo planar images [repetition time (TR) 2000
ms, echo time (TE) 30 ms, flip angle (FA) 78°] with 32 slices, 3.0 mm
thick, in-plane resolution 3 × 3 mm, with slice separation 0.75 mm, in
sequential descending order. A total of 294 volumes were acquired, of
which the first 6 were discarded to allow for steady-state magnetiza-
tion. An MPRAGE T1-weighted structural image was also acquired for
each subject (TR 2250 ms, TE 2.99 ms, FA 9°, inversion time 900 ms,
256 × 256 × 192 isotropic 1 mm voxels) and single-volume turbo
spin-echo (TR 5060 ms, TE 102 ms, FA 140°, 28 × 4 mm slices) for the
purposes of normalization of images, localization of activations on
individual and group brains, and exclusion of significant neurological
comorbidity.
Data pre-processing and analysis used SPM8 (http://www.fil.ion.
ucl.ac.uk/spm) in Matlab 7 environment (R14, Mathworks, CA). fMRI
data were converted from DICOM to NIFTI format, spatially realigned
to the first image and sinc interpolated in time to the middle slice to
correct acquisition delay. The mean fMRI volume and MPRAGE were
coregistered using mutual information, and the MPRAGE segmented
and normalized to the Montreal Neurological Institute T1 template in
SPM by linear and non-linear deformations. The normalization par-
ameters were then applied to all spatiotemporally realigned functional
images, the mean image, and structural images, prior to spatial
smoothing of fMRI data with an isotropic Gaussian kernel 10 mm
FWHM.
First-level statistical parametric modelling for each subject used a
general linear model, modelling the onset of each cue. Five regressors
represented the presentation of the 5 different trial types. Two of the
regressors were for the specified and action-selection repeat trials, in
which subjects pressed the same key as the previous trial. The third
and fourth regressors represented specified and action-selection non-
repeat trials in which a repeat press was unavailable and thus the
response was different to the previous trial. The final fifth regressor
represented repeat-reject action-selection trials in which a repeat
option was available but subjects selected a different option.
Contrasts of interest were between: repeat and non-repeat action-
selection trials [0 1 0 −1 0]; repeat and non-repeat specified trials
[1 0 −1 0 0]; repeat action-selection versus repeat specified trials
[−1 1 0 0 0]; non-repeat action-selection versus non-repeat specified
trials [0 0 −1 1 0]; repeat action-selection versus repeat-reject trials
[0 1 0 0 −1]; non-repeat action-selection versus repeat-reject trials
[0 1 0 0 −1]; all specified and all action-selection trials ([3 −2 3 −2 −2]).
Two second-level random-effects models were used, which included
contrast of interest images from each subject’s analysis at the first
level. The first second-level analysis of variance (ANOVA), corrected
for repeated measures, had 4 regressors specifying the 2 sessions for
Figure 1. The 3-choice action-selection task. The first and last trial in this example sequence are types of specified trials, in which the finger to press is indicated by a black
opaque circle. The second and third are examples of action-selection trials in which the subject can select any 1 of the 3 options highlighted by the black circles. In the second
trial illustrated, there is the option to repeat a response. A repeat action-selection trial would occur if in the second trial the index finger is selected. Conversely, if in the second
trial the ring finger was selected, this would be a “repeat-reject” trial, since the repetition was available but not used. A non-repeat action-selection trial would occur in trial 3, if
in the second trial the index finger was selected, as this option is not available in trial 3.
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controls and the 2 sessions for patients. Two additional regressors
were included to test the effects of disease severity: the mean cor-
rected patients UPDRS score when “on” and mean corrected UPDRS
score when “off” medication. The effects of interest compared
patients with controls (e.g. [1 1 −1 −1 0 0]) and patients in the “on”
and “off” states ([0 0 1 −1 0 0]). To examine an interaction between
disease severity (UPDRS) and medication state, a contrast of [0 0 0 0
1 −1] was used. An additional second-level ANOVA specifically exam-
ined interactions in the prefrontal cortex for repeating and switching
responses in the action-selection condition. This model also included
4 regressors for each of 2 first-level contrasts, “repeat action-
selection” versus “repeat specified trials” and “non-repeat action-
selection” versus “non-repeat specified trials”, and regressors for the
measure of disease severity (UPDRS). SPM(t) maps were generated
using t-contrasts for each effect of interest, thresholded such that
family-wise error rate (FWE) was p < 0.05 for cluster-level whole-
brain comparisons. The voxel-level threshold used to define the clus-
ters was P < 0.001.
A region-of-interest (ROI) analysis aimed to focus on prefrontal
activations that have been previously reported for action-selection
(Rowe, Hughes, Eckstein et al. 2008; Hughes et al. 2010). Activity was
inclusively masked, within left and right dorsolateral and ventrolateral
prefrontal cortex as defined by the pickatlas software toolbox (Mal-
djian et al. 2003; Maldjian et al. 2004), thresholded at FWE P < 0.05
for voxel-wise comparisons (see Fig. 3D).
Results
Behavioural Data
A 3-factor repeated-measures ANOVA of the reaction time data
compared the trial type (specified vs. action-selection trials),
response type (repeat vs. non-repeat), and medication status
(“on” vs. “off”) for patients versus controls. Reaction times for
the specified trials were faster than the action-selection trials
(specified trial mean = 715 ms, SE = 19, action-selection mean
= 800 ms, SE = 23; F(1,32) = 96, P < 0.01), the repeat trials were
faster than the non-repeat trials (repeat trials mean = 735 ms,
SE = 20, non-repeat trials mean = 780 ms, SE = 23; F(1,32) = 20,
P < 0.01), and the controls were faster than the patients
(patients mean: 828 ms SE = 31; controls mean: 687 ms, SE =
29; F(1,32) = 10.7, P < 0.01). There were no significant inter-
actions between any factors (Fig. 2A). Note that the “off” reac-
tion times were not slower than “on” reaction times for
patients. This indicates that the medication state did not
change patients’ ability to respond to the cues and complete
the task, even when “off”, and reduces a potential ambiguity
in the interpretation of imaging data arising from differential
response times.
An ANOVA of the proportion of repetition rates (i.e. when
a repeat option was available, the number of times the subject
repeated) did not reveal any overall categorical differences
between the patients and the controls (chance level 0.33; “on”
patient mean repetition = 0.42, SD 0.24, “off” patient mean =
0.42, SD = 0.20, control overall mean = 0.35, SD = 0.20; F(1,33)
= 1.6, P > 0.05) and there were no interactions of repetition
rates with medication (F(1,33) = 0, P > 0.05). However, the rep-
etition rate was related to the UPDRS measure of disease se-
verity. A Pearson’s correlation between the UPDRS score and
repetition rate for patients “on” medication was significant
showing increased repetition rate in patients with lower
scores (R =−0.51, P = 0.02). For “off” patients there was a
trend between increasing UPDRS scores and increasing rep-
etitions (R = 0.45, P = 0.07) (Fig. 2B). The combination of a
negative correlation for “on” patients and positive correlation
for “off” patients is suggestive of a “U-shaped” function. To
explore this further and to demonstrate the effects of medi-
cation withdrawal on the repetition rate, we examined the
difference in the repetition rate between sessions as a func-
tion of disease severity for subjects included in the imaging
analysis. The change in the repetition rate following withdra-
wal correlated with UPDRS score when “on” (R = 0.5, P <
0.05). Patients with low UPDRS “on” reduced their repetition
rate when dopaminergic treatment was withdrawn, whereas
those with higher UPDRS scores when “on” increased their
repetition rate after treatment was withdrawn (Fig. 2C).
Post-hoc analyses correlating repetition rate with Schwab and
England scores, the disease duration and L-DOPA dose equiv-
alent were not significant.
Figure 2. (A) Reaction times for repeat, repeat-reject and non-repeat trials in the specified and action-selection conditions for patients and controls. Patient reaction times are
slower than for controls, and their repeat trials are faster than the trials in which an alternative response was selected. (B) The proportion of repetitive responses (in trials where
a repetition was available). At chance, repetitions should be ∼0.33. When “on” dopaminergic medication, patients with less disease severity (lower UPDRS) made more
repetitions and this decreased with advancing disease. In contrast, patients “off” medication show a trend of increasing repetitions with increasing disease severity. (C) The
difference in patients’ repetition rates between sessions (proportion of repetitions when “off” minus proportion when “on”) as a function of disease severity, demonstrating the
change in repetition when patients are withdrawn from medication. Patients who have lower UPDRS scores when “on” have a larger reduction in repetition rates when
withdrawn from their medication. As UPDRS increases the difference in repetition rates between sessions decreases. At approximately an UPDRS “on” score of 11 points, the
change in repetition rates starts to increase, such that those patients who have high UPDRS when “on” have increased repetition rates when withdrawn from medication.
Cerebral Cortex July 2013, V 23 N 7 1575
Neuroimaging Results
Action Selection
fMRI demonstrated that for all subjects all action-selection
trials, compared with all specified trials, activated a frontopar-
ietal network, including bilateral superior parietal cortex, left
dorsal premotor cortex, left ventral premotor cortex and left
middle frontal cortex (Table 2, Fig. 3A). This activity is similar
to previously reported networks for action-selection (Rowe,
Hughes, Eckstein et al. 2008; Hughes et al. 2010).
There were no categorical differences in this contrast
between medication states nor between patients and controls.
For patients “off” medication, there was a linear relationship
between the UPDRS score and activity in the left dorsal hip-
pocampus and the right inferior frontal gyrus, with patients
who had the highest scores showing more activity in these
regions (Table 2).
Action Selection: Repetition
Action-selection trials in which subjects chose to repeat an
action, compared with trials in which a repetition was speci-
fied, activated bilateral superior parietal cortex (Table 2). The
effects of PD were revealed by the interaction between
UPDRS and medication state (“on” vs. “off”). This interaction
was significant in bilateral caudate nucleus activation, which
mirrored the pattern of activity in the behavioural data. When
choosing to repeat an action, patients “on” medication with
Figure 3. (A) fMRI activity for all action-selection trials compared with all specified trials for all subjects. Activity is within a broad bilateral frontoparietal network. (P< 0.05
FWE cluster correction.) (B to D) Repetition of responses in patients “on” and “off” medication. (B) BOLD activity in the caudate nucleus for repeat action-selection trials versus
repeat-specified trials. The activity for patients was linearly related to the UPDRS score (cluster-level FWE P< 0.05). (C) The plot of peak voxels within the caudate (xyz=−14
−12 22) depicts this linear relationship. There is a decrease in BOLD activity with increasing UPDRS in patients “on” medication and an increase in activity with increasing
UPDRS in patients “off” medication. (D) BOLD response (red) in ventrolateral PFC for an interaction between repeat action-selection trials versus repeat-specified trials and
non-repeat action–selection trials versus non-repeat–specified trials. The activity was significant within a mask of the PFC (blue) (peak voxels FWE P< 0.05). (E) The plot of
peak voxels within the ventrolateral PFC (xyz= 42, 38, 6) depicts the interaction of BOLD with UPDRS for both trial types: when repeating actions (black diamonds) patients
“on” medication have decreasing activity as UPDRS increases, while patients “off” medication have increasing activity with UPDRS. In non-repeat trials (grey diamonds), the
reverse pattern is observed.
Table 2
Regions of significant activation (FWE cluster-wise whole brain comparison, P< 0.05, except
*FWE corrected within a bilateral prefrontal mask, P< 0.05)
Peak xyz (mm) Cluster size T-statistic
Action selection
All subjects: all action-selection versus specified trials
Bilateral superior parietal cortex 24 −68 52 6022 7.3
−16 −68 58 6.9
Left dorsal premotor cortex −24 0 58 702 5.3
Left ventral premotor cortex −42 4 30 607 5.2
Left middle frontal cortex −46 34 30 5.0
UPDRS patients “off”: all action-selection versus specified trials
Left hippocampus −22 −30 2 372 4.9
Right inferior frontal cortex 48 30 14 601 4.7
Action repetition
All subjects: Repeat action–selection versus repeat specified trials
Bilateral parietal cortex 28 −66 52 391 5.2
−24 −68 56 366 4.3
UPDRS (“on” vs. “off”) repeat action–selection versus repeat specified trials
Bilateral caudate nucleus −14−12 22 710 4.6
20−24 20 4.1
Action switching
All subjects: Non-repeat action-selection versus non-repeat-specified trials
Bilateral parietal cortex −28 −68 52 3176 4.9
22 −70 54 4.6
Right dorsal premotor cortex 26 8 54 408 4.5
Patients “on” UPDRS: non-repeat action–selection versus non-repeat specified trials
Right putamen 26 −14 10 1408 4.4
Patients “off” UPDRS: action-selection repeat versus action-selection non-repeat trials
Right premotor cortex 36 −12 44 586 4.5
Action-repetition versus action switching*
Repeat versus non-repeat trials: Interaction with UPDRS and Medication
Right ventrolateral 58 22 6 4.08
Prefrontal cortex 42 38 6 3.86
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lower UPDRS scores had increased activity in the caudate
nucleus and this activity decreased as the UPDRS score in-
creased. Patients “off” medication showed the opposite
pattern; there was less activity with lower scores which in-
creased as the UPDRS score increased (Fig. 3B and C).
Action Selection: Switching to Alternate Responses
Across all subjects, the action-selection trials in which an al-
ternate action to the previous trial was chosen (all “switch”
trials, including non-repeat and repeat-reject trials), were
compared with trials in which an alternate action was speci-
fied. This response switching behaviour was associated with
activation of bilateral parietal and right premotor cortex
(Table 2).
We next examined the effects of disease and disease sever-
ity on the switch to an alternate response. An effect of
UPDRS for patients “on” medication was evident only in the
non-repeat action-selection trials compared with specified
non-repeat trials. The activity, in the right putamen, increased
as the UPDRS score increased (Table 2). There were also sig-
nificant effects of UPDRS for patients “off” medication, but
only in non-repeat action-selection trials compared with
repeat action-selection trials: when there was no option to
repeat, patients had more activity in right premotor areas
which declined with lower UPDRS scores (Table 2). There
were no differences, and no effects of UPDRS score in the
repeat-reject action-selection trials compared with the other
action-selection trials types, or the specified non-repeat trials.
Action-Selection: Repeating versus Switching
To examine the mechanisms of self-selected repetitive beha-
viours in disease, we used a second-level factorial ANOVA, in-
cluding 2 first-level contrasts and the measure of disease
severity (UPDRS). Specifically, the 2 contrasts were: “repeat
action-selection” versus “repeat specified trials” and “non-
repeat action-selection” versus “non-repeat specified trials”.
The difference between these 2 contrasts was examined to
identify the interaction between repetition and selection of
responses, and the change in this interaction with disease se-
verity. Based on previous studies, we were specifically inter-
ested in activity in the prefrontal cortex and used a bilateral
mask of the left and right lateral prefrontal cortex. The
ANOVA identified a significant interaction with UPDRS in the
right ventrolateral prefrontal cortex. This indicates that when
repeating response selections, compared with switching
responses, the ventrolateral prefrontal cortex decreased in
activity as UPDRS increased in “on” patients. Conversely, in
patients “off” medication this region was increasingly active
as UPDRS increased when repeating responses compared
with switching responses. In other words, the VLPFC showed
increased activity for response repetition by patients who
were less severe and “on”, and for more severe patients when
“off” medication (Table 2 and Fig. 3D and E). The same con-
trast did not reveal an interaction within the caudate, either
within whole-brain analysis (P < 0.001 uncorrected) or within
a post-hoc ROI of the caudate (P < 0.05 corrected).
Discussion
We have demonstrated that the caudate nucleus and ventrolat-
eral prefrontal cortex regulate the perseveration of actions in
PD, but do so according to both motor disease severity
(UPDRS) and dopaminergic medication. Our data illustrate
the interaction between the severity of disease and medication
status in behavioural choices with a U-shaped relationship.
This result goes beyond previous studies which have shown
that repetitions of self-selected responses were increased in
patients “off” medication, and influenced by dopamine
therapy according to task demands (Rutledge et al. 2009;
Hughes et al. 2010).
PD severity altered the activity associated with choosing to
repeat a previous response. In patients “off” medication, as
disease severity increased, the number of chosen repetitions
increased and activity in the caudate nucleus and ventrolateral
PFC increased. This pattern was reversed by dopamine
therapy: when “on” medication, as disease severity increased,
response repetition and activity in these areas decreased. In
trials where repetitions were not available and patients had to
make a new selection, the pattern of activity in the ventrolat-
eral PFC was inverted: activity increased with disease severity
for “on” patients, and decreased with severity for “off”
patients. To explain the complex relationships among these
activations, behaviour, and dopaminergic states, we will first
discuss switching and perseveration in PD and consider the
involvement of the caudate nucleus and the lateral prefrontal
cortex, and the optimization of dopaminergic states.
Perseveration in PD may result from impaired switching
mechanisms. For example, Helmich et al. (2009) report that
patients “off” medication have increased reaction time costs
when choosing to switch actions from the previous trial, and
this cost increases with disease severity (the UPDRS score).
Switching deficits in PD are not restricted to self-selected
actions, but also occur for cued switches (Cools et al. 2001b;
Cools et al. 2003; Kehagia et al. 2009) which are sensitive to
disease severity and dopamine therapy. Further to switching
deficits, a dopamine-dependent “attentional capture” mechan-
ism for salient stimuli is proposed to be affected by PD (Cools
et al. 2010) balancing perseveration with switching and
distractibility.
Our data (Fig. 3) suggest that repetition and switching of
responses in PD is influenced by activity in the VLPFC and
the caudate nucleus. The involvement of both structures im-
plicates a frontostriatal network, although the role of each
structure may differ. This is particularly evident in the inter-
action between repeating and switching responses in the
VLPFC, but not in the caudate. In order to choose to repeat or
switch responses, working memory for previous actions is re-
quired. In health, the lateral prefrontal cortex has been associ-
ated with maintenance of items in working memory
(D’Esposito 2007) and the retrieval or selection of remem-
bered items to guide responses (Rowe et al. 2000; Petrides
2002; Hampshire et al. 2008; Hampshire et al. 2009) or to
identify targets (Hampshire et al. 2008; Hampshire et al.
2009). Thus the contribution of the VLPFC here may be
memory for previous responses to identify repeat or non-
repeat response options.
The activity in the caudate nucleus may be related to the
action or response itself. Patients with caudate lesions have
been described as apathetic and perseverative with impaired
intentional behaviour (Narumoto et al. 2005; Villablanca
2010). Actions in healthy adults also involve the caudate
nucleus in self-selected responses (Provost et al. 2010; Rowe,
Hughes, Nimmo-Smith et al. 2010). The differential activation
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in the current study was within the body of the caudate,
whereas earlier research indicates involvement of the head of
the caudate. However, the body of the caudate is part of the
action network (Robinson et al. 2012) and is active in tasks
which require the planning and execution of self-selected
responses (Monchi et al. 2006; Francois-Brosseau et al. 2009).
However, this leaves the question of why the activation in
both regions is so variable with dopaminergic therapy at
different levels of disease severity?
The observed relationship between perseveration and
neural activity to both disease severity and dopamine therapy
implies a non-linear relationship between dopamine and per-
severation or switching. A compelling approach builds on the
model of a “U-shaped” function, relating dopaminergic state
and function. This captures several related neural, cognitive
and behavioural phenomena, including the differential effects
of dopaminergic treatments on cognitive performance in PD
(Cools et al. 2001a; Rowe, Hughes, Ghosh et al. 2008; Clat-
worthy et al. 2009; Cools and D’Esposito 2011), the effects of
dopaminergic genetic polymorphisms on neural activity
during planning (Williams-Gray et al. 2007), and effects of
baseline differences in striatal dopamine on pharmacological
challenges (Arnsten et al. 1994; Cools et al. 2009). While
some studies infer a U-shaped function from a simple inter-
action between drug and task, or polymorphisms and task
(Cools et al. 2007; Fallon et al. 2012), others use the variance
within the patient population to estimate quadratic relation-
ships between dopaminergic state or disease severity and the
dependent variables (Rowe, Hughes, Ghosh et al. 2008).
Here, we contrast opposing gradients of linear responses (be-
havioural and BOLD) (as used by Wallace et al. 2011) within
“on” and “off” states. This approach clearly illustrates the
potential for a U-shaped function in the caudate nucleus and
VLPFC, in relation to response selection and perseveration.
Two types of mechanism can support such a U-shaped func-
tion. The first is the presence of 2 colocalized opponent systems
subject to dopaminergic regulation, either from different recep-
tor affinities or from distinct functional boundaries. For
example, Durstewitz’ Dual State Theory (Durstewitz and
Seamans 2008) posits a D1-receptor dominated system with
high energy barriers between different neural state represen-
tations (favouring stability, memory, and perseveration) and a
D2-receptor–dominated system with low energy barriers (fa-
vouring switching among representational states). Imbalances
between these D1:D2 systems, and differential affinities, result
in either high perseveration or high switching in response to
dopaminergic stimulation. This explanation is supported by
computational (Cohen et al. 2002) as well as empirical methods
(cf. Williams and Castner 2006; Williams-Gray et al. 2007; Cools
et al. 2009). A second mechanism may coexist to promote a
U-shaped behavioural response to dopaminergic therapy, with
anatomically distinct networks supporting separate elements of
complex cognitive tasks. Distinct circuits, such as parallel
cortico-subcortical loops (Alexander and Crutcher 1990), are
subject to differential progressive pathology in PD (Braak et al.
2006). This network imbalance may be exaggerated by hyper-
dopaminergic compensation in mesocortical systems in early
PD (Rakshi et al. 1999). The result is a set of component
network processes with different optimal dopaminergic states,
such that a unit of dopaminergic stimulation has differential
effects on performance (Rowe, Hughes, Ghosh et al. 2008;
Macdonald and Monchi 2011; MacDonald et al. 2011).
In the current study, the results differ from our previous
study of PD and ageing (Hughes et al., 2010) in which we
used a “4-choice” action-selection paradigm. In the 4-choice
task, all 4 response options were available during each action-
selection trial. The primary effect of this task manipulation is
seen for patients “on” medication, who show opposite trends
in their behaviour: in the 4-choice paradigm, repetitions in-
creased with increasing UPDRS, but in the 3-choice task rep-
etitions decreased with increasing UPDRS. However, the
BOLD response in the ventrolateral PFC shows a similar
pattern in both paradigms for these patients, of decreasing
activity with disease severity for action-selection trials. The
different pattern of results between the 2 tasks suggests that
patients on dopaminergic therapy may be sensitive to the
availability of the responses in the action-selection trials. In
the 4-choice paradigm, all 4 options were always available for
any action-selection trial, enabling subjects to predict the
response options. This predictability means that subjects
could anticipate their response. In the current 3-choice task
however, the 3 options that become available on each action-
selection trial are randomized and thus less predictable. A
further difference between the 2 studies was noted in the be-
haviour of controls, who showed increased repetition rates in
the 3-choice relative to the 4-choice task. This may have been
encouraged from an increase in the repetition rate for speci-
fied trials (which were increased in order to examine the
repeat and the non-repeat trial options).
Nonetheless, in accordance with previous imaging studies
(Deiber et al. 1991; Jenkins et al. 2000; Rowe et al. 2005; For-
stmann et al. 2008; Rowe, Hughes, Eckstein et al. 2008) the
action-selection trials compared with specified trials, engaged
a similar network of frontoparietal activity in health and in
PD. This effect was retained despite the modifications to
examine the repetition of responses more closely.
Although the emphasis in functional imaging studies of PD
is on dopamine neurotransmission, it is noteworthy that PD is
also associated with grey matter atrophy of the lateral prefron-
tal cortex (Burton et al. 2004; Rowe, Hughes, Williams-Gray
et al. 2010) and changes in its underlying white matter (Rae
et al. 2011). Therefore, the progression of PD may be associ-
ated with a changing balance between the anatomical and
neurochemical substrates for memory-based response selec-
tion and this may underlie the U-shaped responses observed
in the caudate nucleus and prefrontal cortex.
Conclusions
PD severity and dopaminergic treatment both influence vo-
luntary action selection. The increase of perseveration with
advancing disease in patients “off” medication is reversed by
dopamine therapy, which increases perseveration in early
disease. We suggest that the caudate nucleus and prefrontal
contributions to selection of actions are not just related to the
presence of choice per se. Instead, these 2 regions form a
frontostriatal network that mediates the choice of response
with reference to a previous trial, and the decision to repeat
or switch to an alternative response.
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